Hydroxysafflor yellow A inhibits the proliferation, migration, and invasion of colorectal cancer cells through the PPARγ/PTEN/Akt signaling pathway

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Katona BW, Weiss JM. Chemoprevention of colorectal cancer. Gastroenterology. 2020 Jan;158(2):368–388.
   PubMed Web of Science ®Google Scholar
• Van der Jeught K, Xu HC, Li YJ, et al. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018 Sep 14;24(34):3834–3848.
   PubMed Web of Science ®Google Scholar
• Bai X, Wang WX, Fu RJ, et al. Therapeutic potential of hydroxysafflor yellow a on cardio-cerebrovascular diseases. Front Pharmacol. 2020;11:01265.
   PubMed Web of Science ®Google Scholar
• Ao H, Feng W, Peng C. Hydroxysafflor yellow A: a promising therapeutic agent for a broad spectrum of diseases. Evid Based Complement Alternat Med. 2018;2018:8259280.
   PubMed Web of Science ®Google Scholar
• Zhang C, Shao Z, Chen Z, et al. Hydroxysafflor yellow A promotes multiterritory perforating flap survival: an experimental study. Am J Transl Res. 2020;12(8):4781–4794.
   PubMed Web of Science ®Google Scholar
• Wu N, Li J, Luo H, et al. Hydroxysafflor yellow A promotes apoptosis via blocking autophagic flux in liver cancer. Biomed Pharmacothe. 2021 Apr;136:111227.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang Y, Zhang L, et al. Hydroxysafflor yellow A of Carthamus Tinctorius L., represses the malignant development of esophageal cancer cells via regulating NF-κB signaling pathway. Cell Biochem Biophys. 2020 Dec;78(4):511–520.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhou LY, Xu N, et al. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways. Thorac Cancer. 2019 Jun;10(6):1319–1333.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Song H, et al. Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation. Biomed Pharmacothe. 2019 Jan;109:806–814.
   PubMed Web of Science ®Google Scholar
• Yang F, Li J, Zhu J, et al. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. Eur J Pharmacol. 2015 May 5;754:105–114.
   PubMed Web of Science ®Google Scholar
• Liu L, Si N, Ma Y, et al. Hydroxysafflor-Yellow A induces human gastric carcinoma BGC-823 cell apoptosis by activating peroxisome proliferator-activated receptor gamma (PPARγ). Med Sci Monit. 2018 Feb 8;24:803–811.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77(1):289–312.
   PubMedGoogle Scholar
• Wagner N, Wagner KD. PPAR Beta/Delta and the Hallmarks of cancer. Cells. 2020 4;9(5):May.
   Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010 Dec 1;49(11):1603–1616.
   PubMed Web of Science ®Google Scholar
• Liang X, Fan X, Tan K, et al. Peroxisome proliferators-activated receptor gamma polymorphisms and colorectal cancer risk. J Cancer Res Ther. 2018 Jun;14(9):S306–s310.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang CY, Liu Z, et al. Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling. Pharm Biol. 2014 Sep;52(9):1085–1093.
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu Q, Huang QX, et al. Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress. Phytomedicine. 2013 May 15;20(7):592–599.
   PubMed Web of Science ®Google Scholar
• Guo X, Qin M, Hong H, et al. Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K/AKT signaling by activating PPARγ/PTEN signaling. Mol Med Rep. 2021;23(5):May.
   Web of Science ®Google Scholar
• Özdemir Z, Utku S, Mathew B, et al. Synthesis and biological evaluation of new 3(2H)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1100–1109.
   PubMed Web of Science ®Google Scholar
• Wang G, Bai X, Jiang G, et al. GIT1 overexpression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. Bioengineered. 2021;12(1):30–43.
   PubMed Web of Science ®Google Scholar
• Liang Z, Xu J, Ma Z, et al. MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9. Bioengineered. 2020 Dec;11(1):70–80.
   PubMed Web of Science ®Google Scholar
• Shang J, Sun S, Zhang L, et al. miR-211 alleviates ischaemia/reperfusion-induced kidney injury by targeting TGFβR2/TGF-β/SMAD3 pathway. Bioengineered. 2020 Dec;11(1):547–557.
   PubMed Web of Science ®Google Scholar
• Han B, Ge Y, Cui J, et al. Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis. Bioengineered. 2020 Dec;11(1):524–535.
   PubMed Web of Science ®Google Scholar
• Papadaki C, Monastirioti A, Rounis K, et al. Circulating MicroRNAs regulating DNA damage response and responsiveness to cisplatin in the prognosis of patients with non-small cell lung cancer treated with first-line platinum chemotherapy. Cancers (Basel). 2020 19; 12(5): May.
   Web of Science ®Google Scholar
• Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, et al. Role of cadherins in cancer-A review. Int J Mol Sci. 2020 Oct 15;21(20):7624.
   PubMed Web of Science ®Google Scholar
• Wong SHM, Fang CM, Chuah LH, et al. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018 Jan;121:11–22.
   PubMed Web of Science ®Google Scholar
• Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011 Sep;68(18):3033–3046.
   PubMed Web of Science ®Google Scholar
• Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. Biomed Pharmacothe. 2019 Oct;118:109320.
   PubMed Web of Science ®Google Scholar
• Yousefnia S, Momenzadeh S, Seyed Forootan F, et al. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity. Gene. 2018 Apr;649(649):14–22.
   PubMedGoogle Scholar
• Park JI, Kwak JY. The role of peroxisome proliferator-activated receptors in colorectal cancer. PPAR Res. 2012;2012:876418.
   PubMed Web of Science ®Google Scholar
• Patel L, Pass I, Coxon P, et al. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 2001 May 15;11(10):764–768.
   PubMed Web of Science ®Google Scholar
• Dai Y, Qiao L, Chan KW, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer. 2008 Jun 15;122(12):2858–2863.
   PubMed Web of Science ®Google Scholar
• Ni J, Zhou -L-L, Ding L, et al. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Exp Cell Res. 2017 Dec 15;361(2):246–256.
   PubMed Web of Science ®Google Scholar
• Fang H, Fang W, Cao H, et al. Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPARγ/PTEN/AKT pathway in differentiated human embryonic stem cells. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2019 Sep;131:110552.
   Google Scholar
• Narayanankutty A. PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence. Curr Drug Targets. 2019;20(12):1217–1226.
   PubMed Web of Science ®Google Scholar
• Duan S, Huang W, Liu X, et al. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Cancer Res. 2018 Dec 5;37(1):304.
   PubMed Web of Science ®Google Scholar